Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.

Tytuł:
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Autorzy:
Remon J; Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain.
Pignataro D; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy.
Novello S; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy. Electronic address: .
Passiglia F; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy.
Źródło:
Cancer treatment reviews [Cancer Treat Rev] 2021 Apr; Vol. 95, pp. 102178. Date of Electronic Publication: 2021 Mar 10.
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Publication: 2003- : Amsterdam : Elsevier
Original Publication: London, New York, Academic Press.
MeSH Terms:
Gene Rearrangement*
Molecular Targeted Therapy*
Anaplastic Lymphoma Kinase/*genetics
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Protein-Tyrosine Kinases/*genetics
Proto-Oncogene Proteins/*genetics
Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Proto-Oncogene Proteins/antagonists & inhibitors
Contributed Indexing:
Keywords: ALK; Crizotinib; Liquid biopsy; Lorlatinib; Lung cancer; ROS1
Substance Nomenclature:
0 (Protein Kinase Inhibitors)
0 (Proto-Oncogene Proteins)
EC 2.7.10.1 (ALK protein, human)
EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
EC 2.7.10.1 (Protein-Tyrosine Kinases)
EC 2.7.10.1 (ROS1 protein, human)
Entry Date(s):
Date Created: 20210320 Date Completed: 20210412 Latest Revision: 20210412
Update Code:
20240105
DOI:
10.1016/j.ctrv.2021.102178
PMID:
33743408
Czasopismo naukowe
Non─small cell lung cancer (NSCLC) presents different druggable genetic abnormalities, including ROS1 and ALK rearrangements, which share relevant clinical features and therapeutic strategies. The homology between the tyrosine kinase domains of ROS1 and ALK defines unique subsets of patients highly sensitive to targeted tyrosine kinase inhibitors (TKIs). Genomic profiling in advanced NSCLC is standard, immunohistochemistry and fluorescence in situ hybridization being the main techniques used to detect genomic rearrangements. Personalized treatment with TKIs in ROS1- and ALK-positive NSCLC patients has dramatically improved patients' outcomes. Crizotinib has been the first-line standard of care treatment in ALK-rearranged NSCLC patients for a long time, while crizotinib still represents the best upfront therapeutic option in ROS1-positive NSCLC patients, followed by next-generation TKIs at the time of disease progression. However, the improved intracranial efficacy of next-generation TKIs has led to these drugs becoming first-line options, widening treatment opportunities for these patients. Since all patients will develop disease progression under TKI therapy, understanding the mechanisms of acquired resistance is crucial to define the optimal sequential therapeutic strategy. Despite the positive correlation between personalized treatment and patients' outcome, access to next-generation TKIs and genomic profiling at the time of disease progression are major challenges to achieving this goal. In this review, we present updated evidence on ROS1- and ALK-rearranged NSCLC regarding epidemiology and diagnostics, current therapies and the most suitable sequential treatment approaches, as well as mechanisms of acquired resistance and strategies to overcome them.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies